Aims Dostarlimab is a PD-1 inhibitor approved provisionally in Australia as monotherapy for patients with dMMR A/R EC that has progressed on/after a platinum-containing regimen. Efficacy and safety in two expansion cohorts of the multicenter, open-label, single-arm Phase I GARNET trial are reported (third interim analysis).
Methods Patients with A/R EC were assigned to Cohort A1 (dMMR/MSI-H) or A2 (MMRp/MSS);receiving dostarlimab 500 mg IV Q3W X4, then 1000 mg Q6W until disease progression, discontinuation, or withdrawal. Primary endpoints were ORR and DOR by blinded independent central review (RECIST v1.1).
Results 153 dMMR/MSI-H and 161 MMRp/MSS patients were enrolled/dosed; 143 and 156 patients were in the efficacy-evaluable population, respectively (measurable disease at baseline; ≥6 months follow-up). ORRs (95% CI) were 45.5% (37.1–54.0; dMMR/MSI-H) and 15.4% (10.1–22.0; MMRp/MSS). Median (m) DOR (95% CI) was not reached (NR) (1.18+ to 47.21+; dMMR/MSI-H) and 19.4 months (2.80–47.18+; MMRp/MSS). 6-, 9-, and 12-month PFS was 49.5%, 48.0%, and 46.4% in dMMR/MSI-H EC and 35.8%, 31.3%, and 29.4% in MMRp/MSS EC, respectively. mOS (95% CI) was NR (25.7–NR; dMMR/MSI-H) and 16.9 months (13.0–21.8; MMRp/MSS).
27 patients (8.6%) discontinued treatment because of a treatment-related adverse event (TRAE). The majority of TRAEs were Grade 1/2; most common any-Grade TRAEs were fatigue (56; 17.8%), diarrhea (46; 14.6%), and nausea (43; 13.7%). No deaths were attributed to dostarlimab. Hypothyroidism (12; 8%) was the most common any-Grade immune-related TRAE.
Conclusions Dostarlimab demonstrated durable antitumor activity in A/R EC. dMMR/MSI-H was associated with higher ORR and longer PFS/OS. Safety was consistent with other PD-1 antibodies.
Funding GSK (213346 [NCT02715284]). ©2022 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2022 ASCO Annual Meeting. All rights reserved. Presented on behalf of original authors with permission. 10.1200/JCO.2022.40.16_suppl.5509–5509.